Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.

S Scalera,B Ricciuti,M Mazzotta,N Calonaci,Joao V Alessi, L Cipriani,G Bon, B Messina,G Lamberti,A Di Federico,F Pecci,S Milite,E Krasniqi,M Barba,P Vici,A Vecchione,F De Nicola, L Ciuffreda, F Goeman, M Fanciulli, S Buglioni, E Pescarmona, B Sharma, K D Felt,J Lindsay,S J Rodig,R De Maria,G Caravagna,F Cappuzzo, G Ciliberto, M M Awad,M Maugeri-Saccà

Annals of oncology : official journal of the European Society for Medical Oncology（2022）

引用 3|浏览39

暂无评分

摘要

KEAP1 C-LOH mutations are associated with an immune-excluded phenotype and worse clinical outcomes among advanced LUAD patients treated with ICIs. By contrast, survival outcomes of patients whose tumors harbored KEAP1 CD-SC mutations were similar to those with KEAP1 wild-type LUADs.

查看译文

关键词

KEAP1,clonal mutations,immunotherapy,loss of heterozygosity,lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要